ADC

51개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved51 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleAbbViePhase 2

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Metastatic Colorectal Cancer · Non Small Cell Lung Carcinoma

#NonSmallCellLungCarcinoma#ADC#Phase2#antibody-drug-conjugate#MetastaticColorectalCancer+1
Trials 13Status Recruiting
ADCLimited DatastaleRochePhase 2

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 12Status Recruiting
ADCLimited DatastaleLepu Biopharma Co., Ltd.Phase 2

Becotatug Vedotin and Pucotenlimab (Becotatug Vedotin and Pucotenlimab)

Hypopharyngeal Squamous Cell Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#ADC#Phase2#antibody-drug-conjugate#HypopharyngealSquamousCellCarcin+1
Trials 11Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Lymphoma+3
Trials 10Status Active
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin (glembatumumab vedotin)

Advanced Malignant Solid Neoplasm; Estrogen Receptor Negative · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#AdvancedMalignantSolidNeoplasm+2
Trials 9Status Active
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Raludotatug deruxtecan (Raludotatug deruxtecan)

Carcinoma, Non-Small-Cell Lung · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 7Status Recruiting
ADCLimited DatastaleMing-Yuan ChenPhase 3

Neoadjuvant and Adjuvant Becotatug Vedotin (Neoadjuvant and Adjuvant Becotatug Vedotin)

Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous

#LocallyAdvancedHeadandNeckSquamo#ADC#Phase3#antibody-drug-conjugate#Ming-Yuan
Trials 6Status Recruiting
ADCLimited DatastaleSeagen Inc.Phase 2

ladiratuzumab vedotin (ladiratuzumab vedotin)

Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SmallCellLungCancer+3
Trials 5Status Active
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

sigvotatug vedotin (sigvotatug vedotin)

Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small Cell Lung

#CarcinomaNon-SmallCellLung#ADC#Phase1#antibody-drug-conjugate#Carcinoma+3
Trials 5Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

5-hydroxytryptamine subtype 3 receptor antagonist (5-hydroxytryptamine subtype 3 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 4Status Recruiting
ADCLimited DatastaleSeagen Inc.Phase 2

denintuzumab mafodotin (denintuzumab mafodotin)

Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-cell

#LymphomaB-cell#ADC#Phase2#antibody-drug-conjugate#Lymphoma+2
Trials 4Status Discontinued
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus chidamide (Consolidation therapy- 3 or 6 cycles of BvC, Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
ADCLimited DatastaleSeagenPreclinical

Brentuximab vedotin plus Chidamide (Induction therapy-3 cycles of BvC, Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide))

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#antibody-drug-conjugate#CD30+PeripheralT-cellLymphoma+1
Trials 3Status Recruiting
ADCLimited DatastaleMacroGenicsPhase 2

vobramitamab duocarmazine (vobramitamab duocarmazine)

Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+2
Trials 3Status Discontinued
ADCLimited DatastaleDaiichi SankyoPhase 2

Patritumab (Patritumab)

Head and Neck Neoplasms · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#ADC#Phase2#antibody-drug-conjugate#HeadandNeckNeoplasms+1
Trials 2Status Active
ADCLimited DatastaleGenentech, Inc.Phase 2

Pinatuzumab Vedotin (Pinatuzumab Vedotin)

Follicular Lymphoma; Diffuse Large B-Cell Lymphoma · Follicular Lymphoma

#FollicularLymphoma#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+1
Trials 2Status Active
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
ADCLimited DatastaleWest China HospitalPhase 2

Becotatug Vedotin Combined with Ivonescimab (Becotatug Vedotin Combined with Ivonescimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#West
Trials 1Status Recruiting
ADCLimited DatastaleFeng LiuPhase 2

Becotatug Vedotin Combined with PD-1 Inhibitor (Becotatug Vedotin Combined with PD-1 Inhibitor)

Head and Neck Squamous Cell Carcinoma · PD-1

#PD-1#ADC#Phase2#antibody-drug-conjugate#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleWest China HospitalPhase 2

Becotatug Vedotin Combined with Penpulimab (Becotatug Vedotin Combined with Penpulimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#West
Trials 1Status Recruiting

2 / 3 pages

← PreviousNext →